



GODAVARI DRUGS LIMITED

Regd. Off.: 'Mayfair', S.P. Road, Secunderabad - 500 003. TS, India.

Date: 27.05.2026

To,
The Secretary
BSE Limited,
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai-400 001.
Scrip code: 530317

Dear Sirs/Madam,

Sub: Outcome of the Board Meeting of Godavari Drugs Limited held on Wednesday 27th May, 2026

Ref: Reg. 30 read with Reg. 33 of SEBI (LODR) Regulations, 2015

A. Pursuant to Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we inform you that the Board of Directors of the Company at its meeting held today i.e. 27th May, 2026, (commenced at 03:30 p.m. and concluded at 04:30 p.m.) inter alia, approved the following;

1. Audited Financial Results:

- a) The Audited Financial Results of the Company for the quarter and Financial Year ended March 31, 2026, as reviewed and recommended by Audit Committee and approved by the Board of Directors are enclosed herewith. The Auditor's Report adopted by the Board of Directors also forms part of the same.

A copy each of the Audited Financial Results as reviewed by the Audit Committee and approved by the Board along with the Auditor's Report issued by our Statutory Auditors, M/s Ayyadevara & Co., Chartered Accountants on the above Financial Results pursuant to Regulation 33 of Listing Regulations is enclosed herewith. The said results are also being uploaded on the website of the Company viz., www.godavaridrugs.com.

We further confirm that the Auditor Report issued by the statutory auditors on the Audited Financial Results of the Company for the quarter and financial year ended 31.03.2026 is with unmodified opinion.

- b) A Declaration under Regulation 33(3)(d) of SEBI LODR Regulations, 2015 pertaining to Audit Report with unmodified opinion on the Audited Financial Results of the Company for the Financial Year ended March 31, 2026, is enclosed herewith.
2. Based on the recommendation of the Audit Committee of the Company, the Board has considered and approved the appointment of M/s. S.K. Lahoti Associates., Chartered Accountants as Internal Auditors of the Company for the Financial Year 2026-27 (**Brief profile is provided**)
3. Based on the recommendation of the Audit Committee of the Company, the Board has considered and approved the appointment of M/S. Bharathula & Associates, Practicing Cost Accountants as Cost Auditors of the Company for the Financial Year 2026-27, subject to ratification of remuneration by the shareholders at the ensuing Annual General Meeting (**Brief profile is provided**)
4. Convening of the 38th Annual General Meeting of the Members of the Company on Friday, 25th September, 2026 at 03.00 p.m. through Video-Conferencing ("VC")/ Other Audio Visual Means ("OAVM") in accordance with relevant circulars issued by the Ministry of Corporate Affairs, Government of India and Securities and Exchange Board of India.



GODAVARI DRUGS LIMITED

Regd. Off.: 'Mayfair', S.P. Road, Secunderabad - 500 003. TS, India.

Disclosure of information with regard to the above mentioned appointments as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Para-A of Schedule-III are provided below as Annexure-A.

This is for your information and records.

Thanking You,

For Godavari Drugs Limited

Venkatesh Achanta

Company Secretary & Compliance Officer

Membership Number : A53326



GODAVARI DRUGS LIMITED

Regd. Off.: 'Mayfair', S.P. Road, Secunderabad - 500 003. TS, India.

ANNEXURE-A

Details as required under Part A of Schedule III and Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circulars No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 and No. SEBI/HO/CFD/CFDPoD1/P/CIR/2023/123 dated July 13, 2023, concerning the appointments and resignations is provided below:

Sl. No.	Particulars	S.K. Lahoti Associates	M/S. Bharathula & Associates
1	Reason for Change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment of M/s. S.K. Lahoti Associates., Chartered Accountants as Internal Auditors of the Company	Appointment of M/s. Bharathula & Associates as Cost Auditor of the Company (Firm Registration No. 101019)
2	Date of Appointment / Cessation	Appointed on 27-05-2026	Appointed on 27-05-2026
3	Terms of appointment	For one year i.e, FY 2026-27 For conducting Internal Audit of the company for the Financial Year 2026-27	For conducting Cost Audit of the company for the Financial Year 2026-27
4	Brief profile (in case of appointment)	M/s. S.K. Lahoti Associates., Chartered Accountants, Practicing Chartered Accountants registered with the Institute of Chartered Accountants of India. The firm is being managed by a team of competent and experienced professionals with rich experience.	M/s. Bharathula & Associates., Cost Accountants, Practicing Cost Accountants registered with the The Institute of Cost Accountants of India (ICMAI). The firm is being managed by a team of competent and experienced professionals
5	Disclosure of Relationships with other Directors (in case of appointment)	NA	NA
6	Shareholding, if any in the company	NA	NA
7	Affirmation that the Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority	NA	NA
8	Name of listed entities in which the resigning Director holds directorship	NA	NA



GODAVARI DRUGS LIMITED

Regd. Off.: 'Mayfair', S.P. Road, Secunderabad - 500 003. TS, India.

B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC: Enclosed

C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES: There is no default on loans and debt securities during the Quarter ended 31 March 2026.

S No	Particulars	In INR Lakhs
1.	Loans /revolving facilities like cash credit from banks / financial institutions	0
A	Total amount outstanding as on date	0
B	Of the total amount outstanding, amount of default as on date	0
2.	Unlisted debt securities i.e. NCDs and NCRPS	
A	Total amount outstanding as on date	0
B	Of the total amount outstanding, amount of default as on date	0
3.	Total financial indebtedness of the listed entity including short term and long-term debt	0

D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter) : Enclosed

E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (applicable only for Annual Filing i.e., 4th quarter): Not Applicable



GODAVARI DRUGS LIMITED

Regd. Off.: 'Mayfair', S.P. Road, Secunderabad - 500 003. TS, India.

Date: 27.05.2026

**To,
The Secretary
BSE Limited,
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai-400 001.
Scrip code: 530317**

Subject: Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

I, Mr. MOHIT JAJU, Whole-time Director of Godavari Drugs Limited, hereby declare that the Statutory Auditors of the Company, M/s. Ayyadevara & Co., Chartered Accountants, have issued the Audit Report on the Standalone Financial Results of the Company for the quarter and year ended 31st March, 2026 with an unmodified/unqualified opinion.

This declaration is given in compliance with Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We further confirm that the financial results for the said period do not contain any false or misleading statements or figures and do not omit any material fact which may make the statements or figures contained therein misleading.

Thanking you,

Yours faithfully,
For Godavari Drugs Limited

MOHIT JAJU
Whole-time Director & CFO
DIN: 03405414

**Independent Auditor's Report on Annual Financial Results of the Company
Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015 (as amended)**


To,
The Board of Directors,
Godavari Drugs Limited
Secunderabad.

Opinion:

1. We have audited the accompanying annual financial results ('the Statement') of Godavari Drugs Limited ('the Company') for the quarter and year ended March 31, 2026, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
 - (i) presents financial results in accordance with the requirements of Regulation 33 of the Listing Regulations, and
 - (ii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under section 133 of the Companies Act, 2013 ('the Act'), read with the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India, of the net profit after tax and other comprehensive income and other financial information of the Company for the quarter and year ended March 31, 2026.

Basis for Opinion:

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Statement section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute



[Handwritten signature]

of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Management and Those Charged with Governance for the Statement:

4. This Statement has been prepared on the basis of the annual financial statements and has been approved by the Company's Board of Directors. The Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit/loss and other comprehensive income and other financial information of the Company in accordance with the Ind AS specified under section 133 of the Act, read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.
5. In preparing the Statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
6. The Board of Directors is also responsible for overseeing the Company's financial reporting process.



(Handwritten signature)

Auditor's Responsibilities for the Audit of the Statement:

7. Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing, specified under section 143(10) of the Act, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.
8. As part of an audit in accordance with the Standards on Auditing, specified under section 143(10) of the Act, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:
- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has in place an adequate internal financial control with reference to financial statements and the operating effectiveness of such controls;
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors;
 - Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify



[Handwritten signature]


our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern; and

- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
9. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter:

11. The Statement includes the financial results for the quarter ended 31 March 2026, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to-date figures up to the third quarter of the current financial year, which were subject to limited review by us.

For Ayyadevara & Co.,
Chartered Accountants
FRN: 00278S


Ayyadevara Srinivas
Proprietor
ICAI Membership No. 028803
Hyderabad. May 27, 2026.
UDIN: 26028803QYUVIY8953



GODAVARI DRUGS LIMITED

CIN : L24230TG1987PLC008016

Regd Office : 'Mayfair' S.P.Road, Secunderabad

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED MARCH 31, 2026

Sl. No.	Particulars	Rupees in Lakhs				
		Quarter ended			Year ended	
		31.03.2026 (Audited)	31.12.2025 (Unaudited)	31.03.2025 (Audited)	31.03.2026 (Audited)	31.03.2025 (Audited)
1	Revenue from operations	3316.31	2218.43	2550.26	10580.81	11335.01
2	Other Income	14.12	1.63	10.51	80.51	97.72
3	Total Revenue from operations (1+2)	3330.43	2220.06	2560.77	10661.32	11432.73
4	Expenses					
	(a) Cost of materials consumed	3026.61	1664.11	2172.78	8888.89	8523.96
	(b) Changes in inventories of finished goods & work-in-progress	-489.54	-175.95	-413.17	-1139.13	-358.20
	(c) Employee benefits expense	132.05	157.66	140.12	569.66	502.81
	(d) Depreciation & amortization expense	61.21	61.20	67.15	243.21	244.76
	(e) Finance Costs	95.55	111.12	110.72	397.97	473.20
	(f) Other Expenses	353.17	324.87	339.19	1229.93	1483.66
	Total expenses	3179.05	2143.01	2416.79	10190.53	10870.19
5	Profit before exceptional Items and tax (3-4)	151.38	77.05	143.98	470.79	562.54
6	Exceptional items	10.38	25.13	-	35.51	-
7	Profit before Tax (5+6)	161.76	102.18	143.98	506.30	562.54
8	Tax expense	-32.68	-26.42	-54.67	-97.39	-124.54
9	Net Profit for the period (7-8)	129.08	75.76	89.31	408.91	438.00
10	Other Comprehensive Income					
	(i) Items that will not be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to Items that will not be reclassified to profit or loss	-	-	-	-	-
	(iii) Items that will be reclassified to profit or loss	-	-	-	-	-
	(iv) Income tax relating to Items that will be reclassified to profit or loss	-	-	-	-	-
	Total Other Comprehensive Income (Net of Tax)	-	-	-	-	-
11	Total Comprehensive Income (9+10)	129.08	75.76	89.31	408.91	438.00
12	Paid-up equity share capital (Face Value Rs. 10/- per share)	1012.74	753.05	753.05	1012.74	753.05
13	Other Equity as shown in the Audited Balance Sheet of the previous year	6042.04	-	3581.56	6042.04	3581.56
14	Earnings per share					
	(a) Basic	1.71	1.01	1.19	5.43	5.82
	(b) Diluted	1.64	1.01	1.19	5.36	5.82

- 1) The above results , as reviewed by the Audit Committee, were considered, approved and taken on record by the Board of Directors at its meeting held on May 27, 2026
- 2) The above results were prepared in accordance with Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable
- 3) The format for audited quarterly results as prescribed in SEBI's Circular No. CIR/CFD/CMD/15/2015 dated 30th November, 2015 has been modified to comply with requirements of SEBI's Circular dated 5th July, 2016. Ind AS Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with IND AS.
- 4) The company during the month of March 2026 made a preferential allotment of 25,96,935 equity shares of Rs10 each fully paid at a premium of Rs79 per share. The number of shares post the allotment are 1,01,27,435 as against the earlier 75,30,500. The diluted EPS is calculated on the basis of the post allotted number of shares
- 5) Corresponding figures in previous year / period have been regrouped wherever considered necessary.

For GODAVARI DRUGS LIMITED

Mohit Jaju
Wholetime Director & CFO
DIN: 03405414

Place: Secunderabad
Date : 27.05.2026

Statement of Assets and Liabilities

Particulars	Rupees in Lakhs	
	Year ended (31.03.2026)	Year ended (31.03.2025)
	(Audited)	(Audited)
ASSETS		
1. Non - current assets		
a. Property, plant and equipment	3030.78	3260.88
b. Capital work - in -progress	5653.82	2994.61
c. Investment Property		
d. Goodwill		
e. Other Intangible assets		
f. Intangible assets under development		
g. Biological Assets other than bearer plants		
h. Financial Assets		
(i) Investments	0.01	0.01
(ii) Trade Receivables		
(iii) Loans		
(iv) Other Financial assets	178.85	175.84
i. Deferred tax assets (net)		
j. Other non-current assets		
2. Current assets		
(a) Inventories	4606.41	2794.13
(b) Financial Assets		
(i) Investments		
(ii) Trade Receivables	4358.11	4232.36
(iii) Cash and cash equivalents	1450.93	237.33
(iv) Bank balances other than (iii) above		
(v) Loans	80.90	102.21
(vi) Others (to be specified)		
(c) Current Tax Assets (Net)		
(d) Other current assets	683.32	510.27
Total Assets	20043.13	14307.64
EQUITY AND LIABILITIES		
EQUITY		
(a) Equity Share capital	1012.74	753.05
(b) Other Equity	6042.04	3581.56
(c) Money Received against Share Warrants	525.11	-
LIABILITIES		
1. Non - current liabilities		
(a) Financial Liabilities		
(i) Borrowings	3697.13	2389.52
(ii) Trade payables		
(iii) Other financial liabilities (other than those specified in item (b))		
(b) Provisions	71.66	82.64
(c) Deferred tax liabilities (Net)	180.02	191.84
(d) Other non-current liabilities		
2. Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	3938.71	3773.25
(ii) Trade payables		
(1) Total outstanding dues of microenterprises and small enterprises	73.86	31.59
(2) Total outstanding dues of creditors other than microenterprises and small enterprises	3397.54	2839.01
(iii) Other financial liabilities (Other than specified in (c))		
(b) Other current liabilities	995.10	546.15
(c) Provisions		
(d) Current Tax Liabilities (Net)	109.22	119.03
Total Equity and Liabilities	20043.13	14307.64

For GODAVARI DRUGS LIMITED

Place: Secunderabad
Date : 27.05.2026

Mohit Jaju
Wholetime Director & CFO
DIN: 03405414

GODAVARI DRUGS LIMITED
CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2026

Rupees in lakhs

Particulars	Year ended (31.03.2026)	Year ended (31.03.2025)
	(Audited)	(Audited)
A. Cash Flow from Operating Activities		
Profit before Depreciation, Interest and Tax	1,147.49	1,280.50
Less : Other Income considered separately	(80.51)	(97.72)
Net	1,066.98	1,182.78
(Increase) / Decrease in Inventories	(1,812.29)	(729.09)
(Increase) / Decrease in Receivables	(125.75)	1,709.97
(Increase) / Decrease in Shortterm Loans & Advances	21.31	(12.72)
(Increase) / Decrease in Other Current Assets	(173.06)	(21.34)
Increase / (Decrease) in Current Liabilities	1,215.20	(894.46)
Income Tax Paid	(119.03)	(115.54)
Total A	73.36	1,119.60
B. Cash Flow from Investing Activities		
(Increase)/Decrease in Fixed Assets	(2,672.31)	(1,999.81)
(Increase)/Decrease in Nonr current assets.	(3.00)	(49.12)
Other Income	80.51	97.72
Total B	(2,594.80)	(1,951.21)
C. Cash Flow from Financing Activities		
Increase in Share Capital	259.69	-
Increase in Share Premium	2,051.58	-
Increase in Share Warrants	525.11	-
Increase/(Decrease) in Long Term Borrowings	1,307.61	1,272.78
Increase/(Decrease) in Long Term Provisions	(10.98)	7.07
Interest Paid	(397.97)	(473.20)
Total C	3,735.04	806.65
D. Net Increase/(Decrease) in cash and cash equivalents [A+B+C]	1,213.60	(24.96)
Cash and cash equivalents at the beginning of the year	237.33	262.29
Cash and cash equivalents at the end of the Period (31.03.2026)	1,450.93	237.33
Increase/(-)Decrease	1,213.60	(24.96)

For GODAVARI DRUGS LIMITED

Mohit Jaju
Wholetime Director & CFO
DIN: 03405414

Place: Secunderabad
Date : 27.05.2026



To

Date: 27.05.2026

The Manager
BSE Limited
P. J. Towers, Dalal Street
Mumbai-400001
(BSE Scrip Code: 530317)

Dear Sir/Madam,

Unit: Godavari Drugs Limited

Sub: Statement on Deviation or Variation of funds under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 32 of The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019 this is to inform the Exchanges that there are no deviation(s) or variation(s) in respect of the utilization of the proceeds of the Preferential Issue of the Company during the quarter and year ended on March 31, 2026. Please find enclosed herewith a statement in this regard.

This is for the information and records of the Exchanges, please.

Thanking you.

**Yours faithfully,
For Godavari Drugs Limited**

Mr. Mukund Kakani
Managing Director
(DIN- 00104646)



Encl: as above



Statement of Deviation or Variation in utilization of funds raised

Name of listed entity	Godavari Drugs Limited						
Mode of Fund Raising	Preferential Allotment						
Type of Instrument	Equity						
Date of Raising Funds	18.03.2026						
Amount Raised	4411.73 Lakhs						
Report filed for Quarter ended	Quarter and year ended as on March 31, 2026.						
Monitoring Agency	Not applicable						
Monitoring Agency Name, if applicable	Not applicable						
Is there a Deviation / Variation in use of funds raised	No						
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not applicable						
If Yes, Date of shareholder Approval	Not applicable						
Explanation for the Deviation / Variation	Not applicable						
Comments of the Audit Committee after review	NIL						
Comments of the auditors, if any	NIL						
Sr. No	Original Object	Modified Object, if any	Original Allocation (in Lakhs)	Modified allocation, if any	Funds Utilised (in Lakhs)	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1.	Capital Expenditure for the purpose of manufacturing Active, pharmaceutical Ingredients and intermediates, specialty chemicals in various therapeutic categories including Anti HIV and CNS segments as detailed below: a) Civil construction for production blocks, utilities, platforms, supports, foundations for equipments including finishing consisting of flooring, painting, etc.; b) Procurement and installation of equipments like reactors, heat exchangers, filtration	Not Applicable	11000.00	0	292.65	NA	--






GODAVARI DRUGS LIMITED

Regd. Off.: 'Mayfair', S.P. Road, Secunderabad - 500 003, TS, India.
Voice : +91-40-2784 9700 / 2784 2602 / 2784 4557
E-mail : info@godavaridrugs.com | Website : www.godavaridrugs.com

	equipments, dryers, pumps, pipelines and fittings, structural steel, safety equipments, fire fighting equipments, enhancement of capacity and upgradation of effluent treatment facilities, etc.;						
	c) Augmenting the electrical infrastructure right from incoming line from substation to transformer and distribution upto the equipments consisting of transformers, electrical pannels, cables, lighting, earthing, etc. Erection and commissioning of all the above.						
2.	Working Capital Requirement	Not Applicable	1711.73	0	0	NA	--
3.	Repayment of unsecured loans to promoters and / or Directors	Not Applicable	1600.00	0	0	NA	--



Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction	Details of the counterparty		Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction	
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance	Closing balance
1	Sushma kakni	Mukund Kakani	Spouse	Any other transaction	Rent	2.40	Approved	2.40	0.00	0.00
2	Mohit jaju	Godavari Drugs Limited	Director	Any other transaction	Rent	4.20	Approved	4.20	0.00	0.00
3	Isheir Jaju	Mohit Jaju	Son	Any other transaction	Salary	4.50	Approved	4.50	0.00	0.00
4	Mukund Kakani	Godavari Drugs Limited	Director	Remuneration		9.00	Approved	9.00	0.00	0.00
5	Mohit jaju	Godavari Drugs Limited	Director	Remuneration		9.00	Approved	9.00	0.00	0.00
6	Venkat esh Achant a	Godavari Drugs Limited	Company Secretary	Remuneration		3.90	Approved	3.90	0.00	0.00
7	Ghansham Jaju	Godavari Drugs Limited	Chairman	Interest received		15.64	Approved	15.64	0.00	0.00

8	Mukund Kakani	Godavari Drugs Limited	Director	Interest received		20.49	Approved	20.49	0.00	0.00
9	Mohit Jaju	Godavari Drugs Limited	Director	Interest received		31.36	Approved	31.36	0.00	0.00
10	Sushma Kakani	Mukund Kakani	Spouse	Any other transaction	Sundry Creditors	2.83	Approved	2.83	2.83	5.66
11	Mohit Jaju	Godavari Drugs Limited	Director	Loan		156.21	Approved	156.21	600.00	756.21
12	Mukund Kakani	Godavari Drugs Limited	Director	Loan		89.26	Approved	89.26	390.00	479.26
13	Ghanshyam Jaju	Godavari Drugs Limited	Chairman	Loan		27.53	Approved	27.53	337.00	364.53
Total value of transaction during the reporting period								376.32		

1. The details in this format are required to be provided for all transactions undertaken during the reporting period. However, opening and closing balances, including commitments, to be disclosed for existing related party transactions even if there is no new related party transaction during the reporting period.
2. Where a transaction is undertaken between members of the consolidated entity (between the listed entity and its subsidiary or between subsidiaries), it may be reported once.
3. Listed banks shall not be required to provide the disclosures with respect to related party transactions involving loans, inter-corporate deposits, advances or investments made or given by the listed banks.
4. For companies with financial year ending March 31, this information has to be provided for six months ended September 30 and six months ended March 31. Companies with financial years ending in other months, the six months period shall apply accordingly.
5. Each type of related party transaction (for e.g. sale of goods/services, purchase of goods/services or whether it involves a loan, inter-corporate deposit, advance or investment) with a single party shall be disclosed separately and there should be no clubbing or netting of transactions of same type. However, transactions with the same counterparty of the same type may be aggregated for the reporting period. For instance, sale transactions with the same party may be aggregated for the reporting period and purchase transactions may also be disclosed in a similar manner. There should be no netting off for sale and purchase transactions. Similarly, loans advanced to and received from the same counterparty should be disclosed separately, without any netting off.
6. In case of a multi-year related party transaction:
 - a. The aggregate value of such related party transaction as approved by the audit committee shall be disclosed in the column "Value of the related party transaction as approved by the audit committee".
 - b. The value of the related party transaction ratified by the audit committee shall be disclosed in the column "Value of the related party transaction ratified by the audit committee".
 - c. The value of the related party transaction undertaken in the reporting period shall be reported in the column "Value of related party transaction during the reporting period".
7. "Cost" refers to the cost of borrowed funds for the listed entity.
8. Transactions such as acceptance of fixed deposits by banks/NBFCs, undertaken with related parties, at the terms uniformly applicable /offered to all shareholders/ public shall also be reported.